RT Journal Article
T1 Polycythemia Vera and Essential Thrombocythemia Patients Exhibit Unique Serum Metabolic Profiles Compared to Healthy Individuals and Secondary Thrombocytosis Patients
A1 Gómez Cebrián, Nuria
A1 Rojas Benedicto, Ayelén
A1 Albors-Vaquer, Arturo
A1 Bellosillo, Beatriz
A1 Besses, Carlos
A1 Martínez López, Joaquín
A1 Pineda Lucena, Antonio
A1 Puchades Carrasco, Leonor
AB Most common myeloproliferative neoplasms (MPNs) include polycythemia vera (PV) and essential thrombocythemia (ET). Accurate diagnosis of these disorders remains a clinical challenge due to the lack of specific clinical or molecular features in some patients enabling their discrimination. Metabolomics has been shown to be a powerful tool for the discrimination between different hematological diseases through the analysis of patients’ serum metabolic profiles. In this pilot study, the potential of NMR-based metabolomics to characterize the serum metabolic profile of MPNs patients (PV, ET), as well as its comparison with the metabolic profile of healthy controls (HC) and secondary thrombocytosis (ST) patients, was assessed. The metabolic profile of PV and ET patients, compared with HC, exhibited higher levels of lysine and decreased levels of acetoacetic acid, glutamate, polyunsaturated fatty acids (PUFAs), scyllo-inositol and 3-hydroxyisobutyrate. Furthermore, ET patients, compared with HC and ST patients, were characterized by decreased levels of formate, N-acetyl signals from glycoproteins (NAC) and phenylalanine, while the serum profile of PV patients, compared with HC, showed increased concentrations of lactate, isoleucine, creatine and glucose, as well as lower levels of choline-containing metabolites. The overall analysis revealed significant metabolic alterations mainly associated with energy metabolism, the TCA cycle, along with amino acid and lipid metabolism. These results underscore the potential of metabolomics for identifying metabolic alterations in the serum of MPNs patients that could contribute to improving the clinical management of these diseases.
PB MPDI
SN 2072-6694
YR 2021
FD 2021-01-27
LK https://hdl.handle.net/20.500.14352/6885
UL https://hdl.handle.net/20.500.14352/6885
LA eng
NO Ministerio de Economía, Industria y Competitividad (MINECO)
NO Comunidad Valenciana/ FEDER
DS Docta Complutense
RD 9 abr 2025